CLAREON® PANOPTIX® AND CLAREON® PANOPTIX® TORIC



EXECUTIVE SUMMARY

>2.2 Million
PANOPTIX® IMPLANTS WORLDWIDE[10]

PanOptix® Trifocal IOL provides distance, 60 cm intermediate, and 40 cm near focal points[1]

With **PanOptix®**, 20/20 visual acuity is possible at distance, intermediate, and near[2]

91.6%
of PanOptix® recipients never required spectacles at any distance[3]



Clareon® IOLs have exceptional rotational stability, reduced edge glare, low PCO[4,5] and are glistening free*[6,7]

PanOptix® features a 60 cm intermediate focal point,[1,8] ideally suited to tasks such as working on a computer[9]

99%
of PanOptix® recipients would have the same lens implanted again†[1]

*Defined as modified Miyata grade 0, <25mv/mm2 over 3 years (n=138), and over 9 years (n=20), respectively. †Based on n=1291 PanOptix® recipients. MVs, microvacuoles; PCO, posterior capsule opacification.

1. Modi S et al. *Ophthalmology* 2021;128:197; 2. Kohnen T, et al. *Clin Ophthalmol* 2023;17:155-163. 3. Zhu D, et al. *Ophthalmol Ther*. 2023; Published online ahead of print. doi: 10.1007/s40123-023-00657-5. 4. Alcon Data on File, 2019; 5. Lehmann R et al. *Clin Ophthalmol* 2021;15:1647; 6. Stanojcic N et al. *J Cataract Refract Surg* 2020;46:986; 7. Oshika T J et al. *Cataract Refract Surg* 2020;46:682; 8. Lwowski C et al. *J Cataract Refract Surg* 2021. doi:10.1097/j.jcrs.0000000000000780; 9. Charness N et al. *Proc Hum Factors Ergon Soc Annu Meet* 2008;52:1614. 10. Alcon Data on File, 2022.

PATIENT AND ECONOMIC BURDEN OF PRESBYOPIA



Alcon

PRESBYOPIA IS AN AGE-RELATED IMPAIRMENT

of near vision characterized by a gradual decrease in accommodation of the eye



Presbyopia reduces the eye's ability to stretch the lens and focus on near objects, as a result of age-related changes to the natural elasticity of the lens

UNCORRECTED PRESBYOPIA

can reduce a patient's quality of life and impacts day to day activities

Feel disabled by reduced near vision*[1]



Say presbyopia **impacts** their **ability to read**†[2]



Say presbyopia **impacts** their **ability to use digital devices**†[2]



Report a **decrease in quality-of-life** score*[1]

Report a **low sense of accomplishment** due to impaired vision*[1]



Require help in performing routine activities of daily living*[1]

*Results from a systematic literature review assessing 53 studies[1]; †Based on a total of 81 social media posts that referred to the impact that presbyopia has on an individual's life.[2]

1. Berdahl J *et al. Clin Ophthalmol* 2020;14:3439; 2. Wolffsohn JS *et al. J Med Internet Res* 2020;22:e18306.

CLAREON® PANOPTIX® OPTICAL DESIGN

TRADITIONAL TRIFOCALS

use sequential diffractive optics that require an 80 cm intermediate focal point for a 40 cm near focal point



It has been demonstrated that there is better comfort at 60 cm for intermediate tasks than at 80 cm[2–5]

1. Sudhir RR et al. Asia *Pac J Ophthalmol* (Phila) 2019;8:335; 2. Carson D et al. *J Cataract Refract Surg* 2016;42:1361; 3. Kohnen T et al. *Am J Ophthalmol* 2017;184:52; 4. Charness N et al. Proc Hum Factors Ergon Soc Annu Meet 2008;52:1614; 5. Lwowski C et al. *J Cataract Refract Surg* 2021. doi:10.1097/j.jcrs.0000000000000780.

A TRIFOCAL USING SEQUENTIAL DIFFRACTIVE OPTICS

can obtain a more comfortable intermediate focal point of 60 cm with a near focal point of 30 cm



A near focal point of 33 cm is not recognized by major organizations such as ANSI and AOA, which both define near vision as 40 cm[2,3]

ANSI, American National Standards institute; AOA, American Optometric Association. 1. Sudhir RR et al. Asia *Pac J Ophthalmol* (Phila) 2019;8:335; 2. American Optometric Association. 2011. Optometric Clinical Practice Guideline. Care of the Patient with Presbyopia; 3. American National Standards Institute. 2015. American National Standard for Ophthalmics – Accommodative Intraocular Lenses.

CREATING A FOURTH FOCAL POINT

at 120 cm enables a new 60 cm intermediate, while maintaining a 40cm near focal point



However, energy being directed to a fourth focal point could compromise distance visual performance

1. Sudhir RR *et al. Asia Pac J Ophthalmol (Phila)* 2019;8:335.

PROPRIETARY ENLIGHTEN® OPTICAL TECHNOLOGY

redirects light energy from the 120 cm focal point to distance[1]



This results in the Clareon® PanOptix® Trifocal IOL design with distance, 60 cm intermediate, and 40 cm near focal points[1]

1. Modi S et al. *Ophthalmology* 2021;128:197; 2. Sudhir RR et al. *Asia Pac J Ophthalmol* (Phila) 2019;8:335.

PANOPTIX® TRIFOCAL IOL IS A SINGLE-PIECE, ASPHERIC, NON-APODIZED DIFFRACTIVE LENS





PanOptix® has a 6.0-mm biconvex optic, a central trifocal zone of 4.5 mm, an overall diameter of 13.0 mm, and 0° haptic angulation

Garcia-Perez J *et al. BMC Ophthalmol* 2017;17:72.

PANOPTIX® USES THE PROPRIETARY ENLIGHTEN® TECHNOLOGY[1]

PanOptix® transmits 88% of available light to the retina,* 50% of which is allocated to distance vision, 25% to intermediate vision, and 25% to near vision[1,2]

*At the simulated 3.0-mm pupil size.1

1. Modi S et al. *Ophthalmology* 2021;128:197; 2. Alcon Data on File, 2015.

CLINICAL DATA

A POOLED ANALYSIS OF MULTIPLE STUDIES DEMONSTRATED THAT PANOPTIX® PROVIDES A CONTINUOUS RANGE OF VISION FROM DISTANCE TO NEAR



20/20 visual acuity is now possible at distance, intermediate (66cm), and near (40cm)†

*Pooled analysis data is from six individual studies[1–6], detailed in the slide notes; †Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means ≥3 of the 5 ETDRS chart letters in the line were identified correctly. logMAR, logarithm of the minimum angle of resolution; VA, visual acuity.

1. Kohnen T, et al. *Clin Ophthalmol* 2023;17:155-163.

PANOPTIX® DELIVERS EXCELLENT VISION AT -3.0 D (33CM)



PanOptix® demonstrates 20/25 (0.1 logMAR) VA at -3.0 D (33 cm) across multiple studies

*Pooled analysis data is from six individual studies[1-6], detailed in the slide notes; †Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means ≥3 of the 5 ETDRS chart letters in the line were identified correctly. logMAR, logarithm of the minimum angle of resolution; VA, visual acuity.

1. Kohnen T, et al. *Clin Ophthalmol* 2023;17:155-163.

PANOPTIX® DEMONSTRATES SUPERIOR VA AT INTERMEDIATE DISTANCES COMPARED WITH AT LISA* AND FINEVISION*



PanOptix® maintains a CDVA of 20/25 (0.1 logMAR) or better between 66 cm (-1.50 D) and 50 cm (-2.00 D), which is significantly better compared with AT LISA* and FineVision*

*Trademarks are the property of their respective owners.
CDVA, corrected distance visual acuity; logMAR, logarithm of the minimum angle of resolution; VA, visual acuity.
Carneros-Llorente AM *et al. J Cataract Refract Surg* 2019;45:587.

PANOPTIX® HAS SIMILAR BINOCULAR PHOTOPIC CONTRAST SENSITIVITY COMPARED WITH A MONOFOCAL CONTROL

Mean (±95% CI) photopic binocular contrast sensitivity at Month 6*[1]



There was no clinically meaningful difference in photopic contrast sensitivity between the two groups across spatial frequencies, regardless of the presence of glare†[1]

*Best-case analysis set; †Losses of >0.3 log units at two or more spatial frequencies are considered clinically meaningful.2 CI, confidence interval; cpd, cycles per degree. 1. Modi S et al. *Ophthalmology* 2021;128:197; 2. International Organization for Standardization (ISO). 11979-7:2014. Ophthalmic implants--Intraocular lenses--Part 7: Clinical investigations of intraocular lenses for the correction of aphakia. Available at https://www.iso.org/standard/55684.html (accessed 11 Jan 2022).

PANOPTIX® HAS SIMILAR BINOCULAR MESOPIC CONTRAST SENSITIVITY COMPARED WITH A MONOFOCAL CONTROL

Mean (±95% CI) mesopic binocular contrast sensitivity at Month 6*



There was no clinically meaningful difference in mesopic contrast sensitivity between the two groups across spatial frequencies, regardless of the presence of glare†1

*Best-case analysis set; †Losses of >0.3 log units at two or more spatial frequencies are considered clinically meaningful.2 CI, confidence interval; cpd, cycles per degree. 1. Modi S et al. *Ophthalmology* 2021;128:197; 2. International Organization for Standardization (ISO). 11979-7:2014. Ophthalmic implants--Intraocular lenses--Part 7: Clinical investigations of intraocular lenses for the correction of aphakia. Available at https://www.iso.org/standard/55684.html (accessed 11 Jan 2022).

ASSESS VISUAL DISTURBANCES WITH PANOPTIX®[1]

A questionnaire was developed and validated to assess visual disturbances with PanOptix®[1]. Questionnaire for Visual Disturbance (QUVID) contains **picture-referenced items** for patients to report the **frequency**, **severity**, and **bothersomeness** of glare, halo, starburst, hazy vision, blurred vision, double vision, and negative dysphotopsia[2]



3.1 In the past 7 days, how often did you experience **glare**?

0	1	2	3	4
☐ Never	☐ Rarely	☐ Sometimes	☐ Most of the time	☐ Always

3.2 Using the pictures below, rate how severe your worst experience was with **glare** in the past 7 days. These pictures may not look exactly like what you see, but are a guide to help you choose your answer.

0	1	2	3	4
☐ None	☐ A little	☐ Mild	☐ Moderate	☐ Severe

3.3 In the past 7 days, how much has your **glare** bothered you?

0	1	2	3	4
☐ Not bothered at all	☐ Bothered a little bit	☐ Bothered somewhat	☐ Bothered quite a bit	☐ Bothered very much

Patients can rate the frequency, severity, or bothersomeness of a particular visual disturbance

1. U.S. Food and Drug Administration. Patient-reported outcomes in intraocular lens labeling. Available at https://www.fda.gov/about-fda/clinical-outcome-assessments-coas-medical-device-decision-making/patient-reported-outcomes-intraocular-lens-labeling (accessed 11 Jan 2022); 2. Modi S et al. *Ophthalmology* 2021;128:197.

SEVERE VISUAL DISTURBANCES WERE EXPERIENCED BY LESS THAN 1 IN 6 PANOPTIX® PATIENTS IN THE FDA REGISTRATION TRIAL

Percentage of PanOptix® patients with a "severe" visual disturbance at Month 6*



≤16% of PanOptix® patients experienced a "severe" visual disturbance

*Assessed using the QUVID questionnaire; †n=126; ‡n=127; §n=125.
FDA, US Food and Drug Administration; QUVID, questionnaire for visual disturbance.
Modi S *et al. Ophthalmology* 2021;128:197.

LESS THAN 4.8% OF PANOPTIX® PATIENTS WERE VERY BOTHERED BY ANY VISUAL DISTURBANCES IN THE FDA REGISTRATION TRIAL

Percentage of PanOptix® patients "bothered very much" by visual disturbances at Month 6*



More than 95% of PanOptix® patients were not "bothered very much" by any visual disturbance

*Assessed using the QUVID questionnaire; †n=126; ‡n=127; §n=125.
FDA, US Food and Drug Administration; QUVID, questionnaire for visual disturbance.
Modi S *et al. Ophthalmology* 2021;128:197.

SEVERITY AND BOTHER FROM HALO PROFILES ARE MORE FAVORABLE WITH PANOPTIX® COMPARED WITH AT LISA*

Percentage of patients reporting **"not at all"** for halo severity



Percentage of patients reporting **"not at all"** for halo bother



Compared with AT LISA* patients, 19.7% more PanOptix® patients did not experience any "severe" halos and 17.4% more PanOptix® patients were not bothered at all by any halos

*Trademarks are the property of their respective owners.
†Pearson's chi-squared test; ‡Mantel–Haenszel test.
Asena BS. *J Cataract Refract Surg* 2019;45:587.

NO HAZE, BLUR, DOUBLE VISION, OR DARK AREAS

No PanOptix® patients reported severe or very bothersome hazy vision, blurred vision, double vision, or dark areas

0.0%

Hazy vision, blurred vision, double vision, or dark areas

Percentage of **PanOptix® patients** with a "severe" visual disturbance at Month 6*

0.0%

Hazy vision, blurred vision, double vision, or dark areas

Percentage of **PanOptix® patients** "bothered very much" by a visual disturbance at Month 6*

0% of patients implanted with PanOptix® in the US FDA Registration trial reported "severe" or "very bothersome" hazy vision, blurred vision, double vision, or dark areas

*Assessed using the QUVID questionnaire.
FDA, US Food and Drug Administration; QUVID, questionnaire for visual disturbance.
clinicaltrials.gov. clinicaltrials.gov.NCT03280108 (accessed 11 Jan 2022).

PANOPTIX® PATIENTS CONSISTENTLY DEMONSTRATE SPECTACLE INDEPENDENCE AT ALL DISTANCES[1]

In a meta-analysis of 13 unique clinical studies, 91.6% of PanOptix® IOL patients achieved complete spectacle independence.[1]

PanOptix®
IOL is the most studied trifocal IOL technology[1]

13
studies

513
patients from 14 countries

91.6%
of patients achieved spectacle independence across all distances

91.6% of PanOptix® patients reported never requiring spectacles for any distance[1]

1. Zhu D, et al. *Ophthalmol Ther.* 2023; Published online ahead of print. doi: 10.1007/s40123-023-00657-5

ASSESS PATIENT EXPERIENCE AND SATISFACTION WITH PANOPTIX®[1]

A questionnaire was developed and validated to assess patient experience and satisfaction with panoptix®[1]. The Intraocular Lens Satisfaction (IOLSAT) questionnaire **assesses a patient's subjective quality of vision** with respect to need for spectacles, as well as expectation and satisfaction with their quality of vision[2]



21. Overall, in the past 7 days, how satisfied were you with your vision?

0	1	2	3	4
☐ Very dissatisfied	☐ Dissatisfied	☐ Neither satisfied nor dissatisfied	☐ Satisfied	☐ Very Satisfied

22. Given your vision today, if you had to do it all over, would you have the same lenses implanted again?

0	1
☐ No	☐ Yes

23. Given your vision today, would you recommend the lenses you had implanted to your family or friends?

0	1
☐ No	☐ Yes

Patients can rate how satisfied they are with their vision

1. U.S. Food and Drug Administration. Patient-reported outcomes in intraocular lens labeling. Available at https://www.fda.gov/about-fda/clinical-outcome-assessments-coas-medical-device-decision-making/patient-reported-outcomes-intraocular-lens-labeling (accessed 11 Jan 2022); 2. Modi S et al. *Ophthalmology* 2021;128:197.

PATIENT SATISFACTION IS HIGH AMONG PANOPTIX® PATIENTS[1]

Delight your patients with the most implanted trifocal IOL worldwide[2]

95.3%
were satisfied with their vision*†‡

99%
said they would have the same lens implanted again*†‡

98.4%
said they would recommend the lens to family or friends*†‡

The majority of PanOptix® recipients are satisfied with their vision, would have the same lens implanted again, and would recommend the lens to their family or friends (n=127)

*Month 6 all-implanted analysis set; †Assessed using the validated IOLSAT questionnaire; ‡n=127.
FDA, US Food and Drug Administration; IOLSAT, intraocular lens satisfaction.

1. Modi S et al. *Ophthalmology* 2021;128:197.
2. Alcon Data on File, 2022.

DELIVER EXCEPTIONAL VISUAL OUTCOMES WITH CONFIDENCE[1]

PanOptix® is the most implanted trifocal IOL worldwide.[3]

Provide your patients with[2-4]:

- Exceptional patient satisfaction
- High rates of spectacle independence.

>2.2 Million
PANOPTIX® IMPLANTS WORLDWIDE

1. Kohnen T, et al. *Clin Ophthalmol* 2023;17:155-163.
2. Clareon® PanOptix® Directions for Use.
3. Alcon Data on File, 2022.
4. Zhu D, et al. *Ophthalmol Ther.* 2023; Published online ahead of print. doi: 10.1007/s40123-023-00657-5

CLAREON® MATERIAL AND DESIGN

CLAREON® MATERIAL AND DESIGN

- Aspheric hydrophobic acrylic IOL[1]
- Ultraviolet and blue light filtering hydrophobic acrylate/methacrylate copolymer[1]
- Index of refraction 1.55 at 35°C[1]
- STABLEFORCE™ modified-L haptics[1]
- Low levels of surface haze[2]
- Glistening free*[3,4]

* Defined as modified Miyata grade 0, <25mv/mm2 over 3 years (n=138), and over 9 years (n=20), respectively.

1. Clareon® PanOptix®. Directions for use. Available at www.ifu.alcon.com (accessed 11 Jan 2022); 2. Werner L et al. J Cataract Refract Surg 2019;45:1490; 3. Stanojcic N et al. *J Cataract Refract Surg* 2020;46:986; 4. Oshika T et al. *J Cataract Refract Surg* 2020;46:682;

CLAREON® IOLS HAVE AMONG THE LOWEST LEVELS OF HAZE COMPARED WITH COMPETITOR IOLS

Pixel haze intensity (mean ±95% CI)*

p<0.001 compared with Clareon®



The ultra-smooth optic of Clareon® delivered significantly lower (p<0.001) levels of surface haze compared with several competitor IOLs

*Surface haze and subsurface nanoglistenings were compared *in vitro*, n=10 IOLs per group.
CI, confidence interval.
Werner L *et al. J Cataract Refract Surg* 2019;45:1490.

CLAREON® IOLS DELIVER EXCEPTIONAL ROTATIONAL STABILITY THAT OPTIMIZES ASTIGMATISM CORRECTION

The high rotational stability of the Clareon® PanOptix® IOL instills the confidence that comes from predictable performance.[1,2]

95.3% of **Clareon® PanOptix® Toric IOLs** rotate ≤5° between surgery and day 1 measures.[1]

Studies demonstrated an absolute rotation of **1.8°** at day 1 post-op and **2°** at 6 months post-op (n=124).[2]



1. Alcon Data on File, 2019.
2. Clareon® Toric IOL Directions for Use.

AXIAL DISPLACEMENT AND SIMULATED DIOPTRIC POWER SHIFT

Clareon® and AcrySof® Had the Lowest Axial Displacement and Simulated Dioptric Power Shift Compared with Competitor IOLs

Axial displacement and simulated dioptric power shifts for five compression diameters†



Clareon® IOL demonstrated significantly less axial displacement compared with enVista*, TECNIS*, and Vivinex* IOLs ($p<0.001$)

*Trademarks are the property of their respective owners.
†95% confidence intervals, n=10 IOLs per group.
Lane S *et al. J Cataract Refract Surg* 2019;45:501.

CLAREON® IS DESIGNED TO REDUCE EDGE-ASSOCIATED GLARE AND PCO (1/2)

Distribution of normalized glare/main beam ratio comparison†1



Proprietary edge curvature minimizes glare and positive dysphotopsias



Precision edge design guards against PCO and associated Nd:YAG procedures[2]

*Trademarks are the property of their respective owners.
†At a 550-illumination angle in vitro, n=5 IOLs per group. Nd:YAG, neodymium-doped yttrium aluminum garnet; PCO, posterior capsule opacification. 1. R. Nuijts. The Ophthalmologist. Clareon® IOL: A New Monofocal Platform. Highlights from Alcon's Satellite Symposium, held on October 9, 2017, at the XXXV Congress of the ESCRS, Lisbon, Portugal. 2017. Available at https://theophthalmologist.com/fileadmin/top/issues/1217/images/1217-900_Alcon_SS-new.pdf (accessed 11 Jan 2022); 2. Lehmann R et al. *Clin Ophthalmol* 2021;15:1647.

CLAREON® IS DESIGNED TO REDUCE EDGE-ASSOCIATED GLARE AND PCO (2/2)

Proprietary edge curvature minimizes glare and positive dysphotopsias



Precision edge design guards against PCO and associated Nd:YAG procedures

Clareon® Monofocal has shown low rates of PCO in a prospective, multicenter (16 sites), US study with 1 year of follow up:



Nd:YAG, neodymium-doped yttrium aluminum garnet; PCO, posterior capsule opacification.
Lehmann R *et al. Clin Ophthalmol* 2021;15:1647.

SUMMARY

EXECUTIVE SUMMARY

>2.2 Million
PANOPTIX® IMPLANTS WORLDWIDE[10]

PanOptix® Trifocal IOL provides distance, 60 cm intermediate, and 40 cm near focal points[1]

With **PanOptix®**, 20/20 visual acuity is possible at distance, intermediate, and near[2]

91.6%
of PanOptix® recipients never required spectacles at any distance[3]

Clareon® IOLs have exceptional rotational stability, reduced edge glare, low PCO[4,5] and are glistening free*[6,7]

PanOptix® features a 60 cm intermediate focal point,[1,8] ideally suited to tasks such as working on a computer[9]

99%
of PanOptix® recipients would have the same lens implanted again†[1]

*Defined as modified Miyata grade 0, <25mv/mm2 over 3 years (n=138), and over 9 years (n=20), respectively. †Based on n=1291 PanOptix® recipients. MVs, microvacuoles; PCO, posterior capsule opacification.

1. Modi S et al. *Ophthalmology* 2021;128:197; 2. Kohnen T, et al. *Clin Ophthalmol* 2023;17:155-163. 3. Zhu D, et al. *Ophthalmol Ther*. 2023; Published online ahead of print. doi: 10.1007/s40123-023-00657-5. 4. Alcon Data on File, 2019; 5. Lehmann R et al. *Clin Ophthalmol* 2021;15:1647; 6. Stanojcic N et al. *J Cataract Refract Surg* 2020;46:986; 7. Oshika T J et al. *Cataract Refract Surg* 2020;46:682; 8. Lwowski C et al. *J Cataract Refract Surg* 2021. doi:10.1097/j.jcrs.0000000000000780; 9. Charness N et al. *Proc Hum Factors Ergon Soc Annu Meet* 2008;52:1614. 10. Alcon Data on File, 2022.

BACK-UP SLIDES

THE CUMULATIVE RATE OF SSIS WAS LOW AMONG PANOPTIX® RECIPIENTS

And similar to that of a monofocal control



The single SSI that occurred for the first eye for PanOptix® was an explant of the IOL due to subjective complaints of dissatisfaction with the level of vision

*Safety analysis set, first eyes.
SSI, secondary surgical intervention.
Modi S et al. Ophthalmology 2021;128:197.

CLAREON® IOLS DELIVER AMONG THE LOWEST LEVELS OF SSNGS COMPARED WITH COMPETITOR IOLS

Comparison of glistenings in Clareon® and competitor IOLs



Surface light scatter due to SSNGs (mean ± 95% CI)



Clareon® IOLs demonstrated significantly less light scatter due to SSNGs compared with Eternity W-60, TECNIS OptiBlue, and EnVista IOLs

*Trademarks are the property of their respective owners.
N=10 per group.
CI, confidence interval; SSNG, subsurface nanoglistening. Werner L et al. J Cataract Refract Surg 2019;45:1490.

For indications, contraindications and warnings please refer to the relevant product's instruction for use